U.S. markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
86.48-0.53 (-0.61%)
At close: 04:00PM EDT
86.20 -0.28 (-0.32%)
After hours: 06:09PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close87.01
Bid86.37 x 100
Ask86.52 x 100
Day's Range85.60 - 86.69
52 Week Range85.21 - 129.10
Avg. Volume635,450
Market Cap20.841B
Beta (5Y Monthly)0.23
PE Ratio (TTM)20.99
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BNTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioNTech SE
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
    Fair Value
    Economic Moat
    24 days agoMorningstar
View more
  • InvestorPlace

    The 3 Best Bargain Stocks to Buy in Q2 2024

    Best bargain stocks to buy is a simple but tricky concept. Whenever shares trade lower than an established multiple, whether that by earnings, sales, book or some other metric, there might be a reason for it. In many cases, it’s not a good one. Let’s face reality here. In the age of the internet, it’s difficult for a well-known publicly traded enterprise to be woefully undervalued. That’s because information is readily available. If the market genuinely believed there was value to be extracted,

  • InvestorPlace

    3 Biotech Stocks to Buy for the Next Bull Run: March 2024

    As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market. With advancements in gene editing, personalized medicine and novel therapeutics, the sector is on the cusp of delivering transformative healthcare solutions. The global biotechnology market is set for remarkable growth. It is forecast to soar from $1 trillion in 202


    This Vaccine Maker Sits on Cash Almost Equal to Its Market Value

    This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.